The World Health Organization (WHO) registered the components of a new drug being developed by Hanmi Pharm. Co., Ltd., in its International Nonproprietary Name (INN) database, the company said.
The components of the company’s new bio drugs, LAPSCA-Exendin 4 (diabetes remedy) as Efpeglenatide and LAPSGCSF as Eflapegrastim are now part of the INN.
The INN is a list of the official names used by WHO in order to identify components of medicine, in accordance with the WHO INN Naming guideline, the company said.
Efpeglenatide is a combination of ef and enatide; LAPSGCSF is combination of ef+la (Long-acting) and grastim, according to a company statement.
The company is developing LAPSCA-Exendin4 as a GLP-1 type diabetes remedy that is at the “global 2nd late” stage. LAPSGCSF is going to have the third examination, following a successful clinical test done by the Spectrum company.